Palvella Therapeutics (PVLA) Financials

Income statements

Mar 1, 2024Mar 1, 2023

EPS

-$0.2(+60.5%)-$0.6

TTM EPS

-$0.2(+60.5%)-$0.6

Revenue

--

TTM Revenue

--

Total Expenses

$1.8 M(-61.3%)$4.5 M

Operating Expenses

$1.8 M(-61.3%)$4.5 M

Cost Of Goods Sold

--

TTM Cost Of Goods Sold

--

Gross Profit

--

TTM Gross Profit

--

Gross Margin

--

Operating Profit

-$1.8 M(+61.3%)-$4.5 M

TTM Operating Profit

-$1.8 M(+61.3%)-$4.5 M

Operating Margin

--

Net Income

-$2.5 M(+62.2%)-$6.7 M

TTM Net Income

-$2.5 M(+62.2%)-$6.7 M

Net Margin

--

EBIT

-$1.7 M(+58.1%)-$4.1 M

TTM EBIT

-$1.7 M(+58.1%)-$4.1 M

EBITDA

-$1.7 M(+58.1%)-$4.1 M

TTM EBITDA

-$1.7 M(+58.1%)-$4.1 M

Selling, General & Administrative Expenses

$775.0 K(-16.1%)$924.0 K

TTM SGA

$775.0 K(-16.1%)$924.0 K

Depreciation And Amortization

--

TTM D&A

--

Interest Expense

$805.0 K(-68.8%)$2.6 M

TTM Interest Expense

$805.0 K(-68.8%)$2.6 M

Income Tax

$0.0(0%)$0.0

TTM Income Tax

$0.0(0%)$0.0

PE Ratio

--

PS Ratio

--

Cashflow statements

Mar 1, 2024Mar 1, 2023

Cash From Operations

-$1.1 M(+72.1%)-$4.0 M

TTM CFO

-$1.1 M(+72.1%)-$4.0 M

Cash From Investing

--

TTM CFI

--

Cash From Financing

--

TTM CFF

--

Free Cash Flow

-$1.1 M(+72.1%)-$4.0 M

TTM FCF

-$1.1 M(+72.1%)-$4.0 M

CAPEX

--

TTM CAPEX

--

Dividends Paid

--

TTM Dividends Paid

--

TTM Dividend Per Share

--

TTM Dividend Yield

--

Payout Ratio

--